NRG
BLRX

Nemes Rush Group’s BioLineRX BLRX Stock Holding History

Nemes Rush Group’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$575 Hold
250
– – ﹤0.01% 870
2025
Q4 		$693 Hold
250
– – ﹤0.01% 852
2025
Q3 		$945 Hold
250
– – ﹤0.01% 638
2025
Q2 		$1.14K Sell
250
-50
-17% -$185 ﹤0.01% 644
2025
Q1 		$888 Hold
300
– – ﹤0.01% 653
2024
Q4 		$2.57K Hold
300
– – ﹤0.01% 594
2024
Q3 		$13.4K Hold
300
– – ﹤0.01% 379
2024
Q2 		$6.84K Hold
300
– – ﹤0.01% 446
2024
Q1 		$13.4K Hold
300
– – ﹤0.01% 414
2023
Q4 		$18.8K Hold
300
– – ﹤0.01% 353
2023
Q3 		$21.8K Hold
300
– – ﹤0.01% 331
2023
Q2 		$19.1K Buy
+300
New +$16.6K ﹤0.01% 368

Other funds holding BLRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return

Nemes Rush Group's BLRX Position: Q1 2026 in Review

Nemes Rush Group held its BioLineRX (BLRX) position steady in Q1 2026 at 250 shares worth $575. The position accounts for ﹤0.01% of the portfolio, ranked #870.

Nemes Rush Group first reported a position in BLRX in Q2 2023 and has held it in 12 quarters since. The position peaked at $21.8K in Q3 2023. 13 funds tracked by Wall St. Rank hold BLRX as of Q1 2026.

  • Nemes Rush Group held 250 shares of BioLineRX worth $575 as of Q1 2026.
  • Nemes Rush Group left its BioLineRX share count unchanged in Q1 2026.
  • BioLineRX made up ﹤0.01% of Nemes Rush Group's portfolio in Q1 2026, its #870 holding.
  • Nemes Rush Group first reported a position in BioLineRX in Q2 2023 and has held it in 12 quarters since.
  • Nemes Rush Group's BioLineRX position peaked at $21.8K in Q3 2023.
  • 13 funds tracked by Wall St. Rank held BioLineRX as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.